Feng Jin, chief physician, second-level professor, doctoral supervisor. He has been engaged in clinical and basic research related to the time biology of nasopharyngeal carcinoma for a long time. Hosted "Later course three-dimensional conformal radiotherapy plus time-adjusted chemotherapy for nasopharyngeal carcinoma" won the second prize of scientific and technological progress of Guizhou Medical Association in 2006, and "Research on Time-adjusted Chemotherapy and Radiotherapy and Related Factors of Head and Neck Tumors" won 2012 The third prize of the Guizhou Science and Technology Progress Award in 2016; "The Basic Research and Clinical Application of Time Medicine in Oncology" won the third prize of the 2013 Chinese Medical Science and Technology Award; "Individualized treatment of head and neck tumor time-regulated chemotherapy and radiotherapy "Transformation Application" won the second prize of 2016 Guizhou Province Science and Technology Transformation. As the co-first author, the paper "Gemcitabine combined with cisplatin regimen induction chemotherapy for nasopharyngeal carcinoma" was published in the New England Journal in September 2019. The results of the study rewritten the 2020 NCCN guidelines for nasopharyngeal carcinoma and regarded it as nasopharyngeal carcinoma. The highest level of evidence for treatment (Class IIA) is recommended. (Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.[J] .N Engl J Med. 2019, 381(12):1124-1135. (Co-first author). Related The research results have been exhibited in international and domestic conferences.
Disclosures:
- Employment: none
- Compensation: none
- Ownership: none
- Leadership: none